Developments in radionuclide therapy led to the use of radionuclide-boundpeptides, antibodies or small molecules that seek out specific cancerous cells e.g. in prostate cancer, neuro-endocrine tumors and meningioma. At present, new targeted radiopharmaceutical have been developed and need to be validated for tumor entities such as meningioma or prostate cancer. We aim to evaluate the effectiveness of the new targeted radionuclide therapies in different cancer types.
Contact: Dr. Helmut Dittmann